| Primary information |
|---|
| sequence ID | Seq_4588 |
| Peptide sequence | LAPLAEDVRGNL |
| CancerPDF_ID | CancerPDF_ID79, CancerPDF_ID360, CancerPDF_ID1375, CancerPDF_ID2579, CancerPDF_ID9571, |
| PMID | 16896061,19795908,21136997,21136997,21533267 |
| Protein Name | Apolipoprotein A-IV,Apolipoprotein A-IV,Apolipoprotein A-IV,Apolipoprotein A-IV,Apolipoprotein A-IV |
| UniprotKB Entry Name | APOA4_HUMAN,APOA4_HUMAN,APOA4_HUMAN,APOA4_HUMAN,APOA4_HUMAN |
| Fluid | Serum,Plasma,Serum,Plasma,Serum |
| M/Z | 634.29,634.35,1266.6932,1266.6932,634.35 |
| Charge | 2,2,1,1,2 |
| Mass (in Da) | 1267.69,NA,NA,NA,NA |
| fdr | NA,NA,NA,NA,NA |
| Profiling Technique | MALDI-TOF,LC-MS,LC-MS,LC-MS,LC-MS |
| Peptide Identification technique | Q/TOF MS/MS,MALDI-TOF/TOF,LC-MS-MS/MS,LC-MS-MS/MS,LC/MS/MS |
| Quantification Technique | NA,LC-MRM (multiple reaction monitoring),LC-ESI-MS,LC-ESI-MS,Multiple Reaction Monitoring |
| Labelled/Label Free | Label Free,Labelled,Label Free,Label Free,Label Free |
| FDR | NA,less than 7%,NA,NA,1.49 |
| CancerPDF_ID | CancerPDF_ID79, CancerPDF_ID360, CancerPDF_ID1375, CancerPDF_ID2579, CancerPDF_ID9571, |
| p-Value | 1.00E-05,NA,NA,NA,NA |
| Software | MASCOT,FlexAnalysis 3.0 and Biotools 3.0 software,MASCOT(v. 2.2.01),MASCOT(v. 2.2.01),MASCOT |
| Length | 12,12,12,12,12 |
| Cancer Type | Metastatic thyroid carcinomas,Ductal adenocarcinoma of the pancreas (DAP),Colorectal cancer,Normal,Lung adenocarcinoma |
| Database | NCBI refseq Protein Database,NCBI refseq Protein Database,SwissProt Database,SwissProt Database,Swissprot Database (57.4) |
| Modification | NA,NA,NA,NA,NA |
| Number of Patients | 40 metastatic thyroid carcinoma patients and 40 normal for training phase and 10 metastatic thyroid carcinoma and 10 normal individuals for independent validation,"40 normal, 28 patients",30 patients and 30 healthy controls,27 healthy individuals,62 lung adenocarcinoma and 30 healthy control |
| Regulation | NA,NA,NA,NA,"Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" |
| Validation | Independent validation,NA,Leave One out Cross validation,Leave One out Cross validation,MRM-based validation of 19 candidates |
| Sensitivity | 95% on independent dataset,NA,NA,NA,NA |
| Specificity | 95% on independent dataset,NA,NA,NA,NA |
| Accuracy | NA,NA,NA,NA,NA |
| Peptide Atlas | PeptideAtlas |
| IEDB | |